Secukinumab decreases serum Krebs von den Lungen 6 (KL-6) level in patients with psoriasis with elevated serum KL-6 level

Br J Dermatol. 2018 Dec;179(6):1396-1397. doi: 10.1111/bjd.16993. Epub 2018 Sep 23.

Authors

C Chijiwa¹, S Takeoka¹, M Kamata¹, H Uchida¹, S Fukaya¹, K Hayashi¹, A Fukuyasu¹, T Tanaka¹, T Ishikawa¹, T Ohnishi¹, Y Tada¹

Affiliation

¹ Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.

PMID: 29985537
DOI: 10.1111/bjd.16993

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal, Humanized
Biomarkers / blood
Female
Humans
Interleukin-17 / antagonists & inhibitors
Interleukin-17 / immunology
Lung Diseases, Interstitial / blood
Lung Diseases, Interstitial / immunology
Lung Diseases, Interstitial / prevention & control*
Male
Middle Aged
Mucin-1 / blood*
Psoriasis / blood
Psoriasis / drug therapy*
Psoriasis / immunology
Treatment Outcome

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Biomarkers
IL17A protein, human
Interleukin-17
MUC1 protein, human
Mucin-1
secukinumab